Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
-
New eye implant could slash treatment shots for wet AMD
Disease control OngoingThis phase 3 study tests EYP-1901, a slow-release implant, against standard aflibercept injections in 400 people with wet AMD. The goal is to see if the implant can maintain or improve vision while reducing how often patients need eye injections over 2 years. Participants must ha…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 07:51 UTC
-
New eye drug could cut injection frequency for wet AMD patients
Disease control OngoingThis phase 3 study tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 participants will receive either EYP-1901 or standard aflibercept injections. The goal is to see if EYP-1901 can maintain …
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 07:34 UTC